New PR just out...... https://www.cytodyn.com
Post# of 155147
(Total Views: 939)
Posted On: 07/27/2020 6:00:56 AM
New PR just out......
https://www.cytodyn.com/newsroom/press-releas...to-provide
CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVID-19 Trials
Download as PDFJuly 27, 2020 6:00am EDT
VANCOUVER, Washington, July 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Thursday, July 30, 2020, to provide a comprehensive update on the Company’s two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications.
Management will dedicate approximately 45 minutes to address questions from analysts and investors, as a follow-on to the Q&A session from the recent special meeting of stockholders.
Date: Thursday, July 30, 2020
Time: 1:00 p.m. PT / 4:00 p.m. ET
Dial-In: 877-407-8291 U.S. / 201-689-8345 International
https://www.cytodyn.com/newsroom/press-releas...to-provide
CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVID-19 Trials
Download as PDFJuly 27, 2020 6:00am EDT
VANCOUVER, Washington, July 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Thursday, July 30, 2020, to provide a comprehensive update on the Company’s two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications. Management will dedicate approximately 45 minutes to address questions from analysts and investors, as a follow-on to the Q&A session from the recent special meeting of stockholders.
Date: Thursday, July 30, 2020
Time: 1:00 p.m. PT / 4:00 p.m. ET
Dial-In: 877-407-8291 U.S. / 201-689-8345 International
(0)
(0)